Arcutis Biotherapeutics Inc
NASDAQ:ARQT

  • LAST PRICE
    9.1600
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    9.1600/ 2
  • Ask / Lots
    9.1900/ 3
  • Open / Previous Close
    --- / 9.1600
  • Day Range
    ---
  • 52 Week Range
    1.7600
    13.1700
  • Volume
    1

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Sep 25, 2024

  • Sep 24, 2024

      Show headlines and story abstract

    • 9:04AM ET on Tuesday Sep 24, 2024 by MT Newswires
      Companies Mentioned: ARQT
      09:04 AM EDT, 09/24/2024 (MT Newswires) -- Arcutis Biotherapeutics (ARQT) said Tuesday that the US Food and Drug Administration has accepted its supplemental new drug application for Zoryve foam 0.3% to treat adults and adolescents aged 12 and older...

    • 8:00AM ET on Tuesday Sep 24, 2024 by Dow Jones
      Companies Mentioned: ARQT

      Arcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential of roflumilast foam and regulatory timing for FDA approval based on the PDUFA for the treatment of scalp and body psoriasis; the potential of real-world use results of roflumilast foam, as well as the potential approval of roflumilast foam for scalp and body psoriasis. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the "Risk Factors" section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 27, 2024, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

  • Sep 19, 2024

      Show headlines and story abstract

    • 8:49AM ET on Thursday Sep 19, 2024 by MT Newswires
      Companies Mentioned: ARQT
      08:49 AM EDT, 09/19/2024 (MT Newswires) -- Arcutis Biotherapeutics (ARQT) said Thursday that data from two phase 3 studies reinforced the efficacy and safety of Zoryve cream for the treatment of mild to moderate atopic dermatitis, a form of eczema. ...

    • 8:00AM ET on Thursday Sep 19, 2024 by Dow Jones
      Companies Mentioned: ARQT

      Arcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential of real-world use results of roflumilast cream in AD, and the potential for roflumilast cream to advance the standard of care in AD and other inflammatory dermatological conditions. These statements are subject to substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, and the impact of competition and other important factors discussed in the "Risk Factors" section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 27, 2024, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Peers Headlines